Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data from skin of patients with adverse drug reactions (ADRs)

ABSTRACT: ADRs are immune mediated skin reactions of diverse severity and etiology. The patho-mechanisms are however not well understood. We used a gene expression array for the comparison of the gene expression profile of 2 cutaneous adverse drug reactions (MPR and AGEP) to normal skin.

ORGANISM(S): Homo sapiens

PROVIDER: GSE121421 | GEO | 2019/02/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Expression data from skin of patients with adverse drug reactions (ADRs)

Project description:Expression data from skin of patients with adverse drug reactions (ADRs)

| PRJNA497293 | ENA

Affymetrix SNP array data for pharmacogenomic profile of Benzidazole adverse reactions.

Project description:Search for SNPs associated with the pharmacogenomic profile of Benzidazole adverse reactions in Chagas Disease Homo sapiens patients.

2021-03-31 | GSE154421 | GEO

Affymetrix SNP array data for pharmacogenomic profile of Benzidazole adverse reactions.

Project description:Affymetrix SNP array data for pharmacogenomic profile of Benzidazole adverse reactions.

| PRJNA646225 | ENA

38-502:BRAFTOVI/MEKTOVI Combination Therapy Specified Drug Use Survey(CRC)

Project description:Primary outcome(s): [Safety]Occurrence status of adverse drug reactions and infections, Occurrence status of adverse drug reactions corresponding to specified safety concerns, Factors that are considered to affect safety Specified safety concerns: Cutaneous malignancies, palmar-plantar erythrodysaesthesia syndrome, eye disorders, cardiac dysfunction, hypertension, rhabdomyolysis, hepatic dysfunction, and haemorrhage [Efficacy]Antitumor effect and overall survival (OS)

| 2613085 | ecrin-mdr-crc

GPCR signaling neighborhoods associate with the susceptibility to adverse drug reactions of incretin mimetics

Project description:G protein-coupled receptors are important drug targets that engage and activate signaling transducers in multiple cellular compartments. Delineating therapeutic signaling from signaling associated with adverse events is an important step towards rational drug design. The glucagon-like peptide-1 receptor (GLP-1R) is a validated target for the treatment of diabetes and obesity, but drugs that target this receptor are a frequent cause of adverse events. Using recently developed biosensors, we explored the ability of GLP-1R to activate 15 pathways in 4 cellular compartments and demonstrate that modifications aimed at improving the therapeutic potential of GLP-1R agonists greatly influence compound efficacy, potency and safety in a pathway- and compartment-selective manner. These findings, together with comparative structure analysis, time-lapse microscopy and phosphoproteomics, reveal unique signaling signatures for GLP-1R agonists at the level of receptor conformation, functional selectivity and location bias, thus associating signaling neighborhoods with functionally distinct cellular outcomes and clinical consequences.

2023-10-11 | PXD037472 | Pride

Gene expression profiles in drug-induced hypersensitivity reactions with cutaneous involvement

2009-10-01 | GSE12829 | GEO

Gene expression profiles in drug-induced hypersensitivity reactions with cutaneous involvement

Project description:Hypersensitivity reactions to medications constitute a growing problem in the clinical practice. In order to study the molecular basis underlying the pathogenesis of non-immediate hypersensitivity reactions to drugs, we characterized the gene expression profiles of PBMCs isolated from patients during the acute phase and upon resolution of the clinical symptoms using a cDNA array technology. Eighty five genes were found to be differentially expressed during the acute phase of drug-induced delayed hypersensitivity reactions. Furthermore, ninety two genes with distinct expression patterns during the acute phase of severe and benign diseases were identified. Keywords: Comparison between disease and healty status Expression profiles of 11835 genes were analyzed in peripheral blood mononuclear cells from 13 patients with different clinical entities . Two samples were analyze from each patient. The first blood sample was drawn during the acute phase of the disease. The second blood sample was obtained upon resolutin of the clinical symptoms. The ratio between gene expression levels in both samples was calculated for each patient.

2009-10-01 | E-GEOD-12829 | biostudies-arrayexpress

Homo sapiens

Project description:Identification of drug-specific public TCR driving severe cutaneous adverse reactions

| PRJNA550004 | ENA

Prospective Analysis of Hypersensitivity Reactions to Oxaliplatin

Project description:This research study will examine how often hypersensitivity, or allergic reactions, occur in patients receiving the chemotherapy medication oxaliplatin. Hypersensitivity reactions can vary from a transient skin rash and fever to more severe symptoms such as shortness of breath, chest tightness, and a more severe allergic reaction that can affect blood pressure called anaphylaxis. We will be examining how often hypersensitivity reactions occur and how severe the reactions are when they occur. We will also examine whether there are factors that place people at risk for developing hypersensitivity reactions to oxaliplatin. In an optional portion to this study, we will examine whether allergy skin testing can predict whether someone will develop a hypersensitivity reaction. Participants who develop a moderate to severe allergic reaction to oxaliplatin will be invited to participate in an additional portion of the study examining a desensitization process. This part of the study will examine whether a desensitization process can prevent future hypersensitivity reactions to oxaliplatin in patients who previously developed moderate to severe hypersensitivity reactions and allow therapy with oxaliplatin to continue.

| 2067027 | ecrin-mdr-crc

Pharmacogenomics of adverse drug reactions.

Project description: Not available

| S-EPMC3707028 | biostudies-literature